Inhaled corticosteroids in asthma management.

Asthma is a disorder of the lower airways, characterized by bronchial hyperresponsiveness and airflow limitation, the pathogenesis of which is yet to be fully understood. Regardless of its triggers, asthma's hallmark is a state of inflammation that, when uncontrolled, results in persistence of symptoms. Inhaled corticosteroids are established as the mainstay of asthma therapy. This paper examines what is currently available among this class of drugs, features of the ideal inhaled corticosteroid, the delivery systems, dose-response relationships, adverse effects, combination with long-acting beta agonists, equipotent doses among the different types, and several special scenarios that involve the apparent incomplete or lack of response to treatment with inhaled corticosteroids among certain subgroups of patients, such as smokers and obese individuals, and we will discuss the scientific basis of such resistance and suggest alternative approaches to therapy.

[1]  J. Bestall,et al.  Fluticasone at different doses for chronic asthma in adults and children. , 2008, The Cochrane database of systematic reviews.

[2]  P. Jones,et al.  Fluticasone versus placebo for chronic asthma in adults and children. , 2008, The Cochrane database of systematic reviews.

[3]  Praveen Kumar,et al.  Assessment of the Long-term Safety of Inhaled Ciclesonide on Growth in Children With Asthma , 2008, Pediatrics.

[4]  David Skoner,et al.  Assessment of the Long-term Safety of Inhaled Ciclesonide on Growth in Children With Asthma , 2008, Pediatrics.

[5]  D. Mannino,et al.  Body mass index and asthma severity in the National Asthma Survey , 2007, Thorax.

[6]  P. Paré,et al.  Survival after lung volume reduction in chronic obstructive pulmonary disease: insights from small airway pathology. , 2007, American journal of respiratory and critical care medicine.

[7]  R. H. Levin,et al.  Inhaled corticosteroids for asthma. , 2007, Pediatrics in review.

[8]  N. Barnes.  The properties of inhaled corticosteroids: similarities and differences. , 2007, Primary care respiratory journal : journal of the General Practice Airways Group.

[9]  E. Israel,et al.  Smoking affects response to inhaled corticosteroids or leukotriene receptor antagonists in asthma. , 2007, American journal of respiratory and critical care medicine.

[10]  A. Wanner,et al.  Inhaled corticosteroids reduce asthma-associated airway hyperperfusion through genomic and nongenomic mechanisms. , 2007, Pulmonary pharmacology & therapeutics.

[11]  L. Bacharier,et al.  Management approaches to intermittent wheezing in young children , 2007, Current opinion in allergy and clinical immunology.

[12]  Bartolome Celli,et al.  Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. , 2007, The New England journal of medicine.

[13]  C. Vogelmeier,et al.  Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease. , 2007, American journal of respiratory and critical care medicine.

[14]  H. Bisgaard,et al.  Budesonide/formoterol maintenance plus reliever therapy: a new strategy in pediatric asthma. , 2006, Chest.

[15]  S. Pedersen,et al.  A comparative study of inhaled ciclesonide 160 µg/day and fluticasone propionate 176 µg/day in children with asthma , 2006 .

[16]  R. Lipchik.  Addition of salmeterol to usual asthma pharmacotherapy may increase respiratory related deaths or life threatening experiences , 2006, Evidence-based medicine.

[17]  R. Dahl.  Systemic side effects of inhaled corticosteroids in patients with asthma. , 2006, Respiratory medicine.

[18]  Bradley E. Chipps.  Daily Versus As-Needed Corticosteroids for Mild Persistent Asthma , 2006, Pediatrics.

[19]  I. Adcock,et al.  Relative corticosteroid insensitivity of peripheral blood mononuclear cells in severe asthma. , 2006, American journal of respiratory and critical care medicine.

[20]  A. Chuchalin,et al.  EXCEL: A randomised trial comparing salmeterol/fluticasone propionate and formoterol/budesonide combinations in adults with persistent asthma. , 2006, Respiratory medicine.

[21]  F. Cerasoli.  Developing the ideal inhaled corticosteroid. , 2006, Chest.

[22]  J. Oppenheimer.  Device Selection and Outcomes of Aerosol Therapy: Evidence-Based Guidelines , 2006 .

[23]  Vernon M Chinchilli,et al.  Long-term inhaled corticosteroids in preschool children at high risk for asthma. , 2006, The New England journal of medicine.

[24]  I. Adcock,et al.  Update on glucocorticoid action and resistance. , 2006, The Journal of allergy and clinical immunology.

[25]  W. Berger.  Paediatric pulmonary drug delivery: considerations in asthma treatment , 2005, Expert opinion on drug delivery.

[26]  J. Cowan,et al.  Use of exhaled nitric oxide measurements to guide treatment in chronic asthma. , 2005, The New England journal of medicine.

[27]  M. Zitt.  Properties of the ideal corticosteroid therapy. , 2005, Allergy and asthma proceedings.

[28]  R. Shiner,et al.  Methotrexate therapy of oral corticosteroid‐dependent asthmatics reduces serum immunoglobulins: correlation with clinical response to therapy , 2005, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[29]  N. Thomson,et al.  Efficacy of low and high dose inhaled corticosteroid in smokers versus non-smokers with mild asthma , 2005, Thorax.

[30]  D. Sin,et al.  Pharmacological management to reduce exacerbations in adults with asthma: a systematic review and meta-analysis. , 2004, JAMA.

[31]  M. Weatherall,et al.  The dose-response relationship of inhaled corticosteroids in asthma , 2004, Current allergy and asthma reports.

[32]  F. Chiarelli,et al.  Adrenal suppression from high-dose inhaled fluticasone propionate in children with asthma , 2004, European Respiratory Journal.

[33]  H. Bisgaard.  Effect of long‐acting β2 agonists on exacerbation rates of asthma in children , 2003, Pediatric pulmonology.

[34]  G. Colice,et al.  Inhaled corticosteroids: past lessons and future issues. , 2003, The Journal of allergy and clinical immunology.

[35]  J. Banks.  SIGNIFICANT VARIABILITY IN RESPONSE TO INHALED CORTICOSTEROIDS FOR PERSISTENT ASTHMA , 2003, Pediatrics.

[36]  I. Danta,et al.  Comparative bronchial vasoconstrictive efficacy of inhaled glucocorticosteroids , 2003, European Respiratory Journal.

[37]  Richard J Martin,et al.  Relations between exhaled nitric oxide and measures of disease activity among children with mild-to-moderate asthma. , 2003, The Journal of pediatrics.

[38]  R. Dahl,et al.  Effects of salmeterol on mucosal inflammation in asthma: a placebo-controlled study , 2002, European Respiratory Journal.

[39]  R. Pauwels,et al.  Gene expression and immunolocalization of 15-lipoxygenase isozymes in the airway mucosa of smokers with chronic bronchitis. , 2002, American journal of respiratory cell and molecular biology.

[40]  R. Lemanske,et al.  Omalizumab improves asthma-related quality of life in children with allergic asthma. , 2002, Pediatrics.

[41]  Stephen C Lazarus,et al.  Systemic effect comparisons of six inhaled corticosteroid preparations. , 2002, American journal of respiratory and critical care medicine.

[42]  K. J. Macleod,et al.  Influence of cigarette smoking on inhaled corticosteroid treatment in mild asthma , 2002, Thorax.

[43]  P. J. Barnes.  Scientific rationale for inhaled combination therapy with long-acting β2-agonists and corticosteroids , 2002, European Respiratory Journal.

[44]  A. Herxheimer,et al.  Dose-response relation of inhaled fluticasone propionate in adolescents and adults with asthma: meta-analysis. , 2001, BMJ : British Medical Journal.

[45]  R J Adams,et al.  Impact of Inhaled Antiinflammatory Therapy on Hospitalization and Emergency Department Visits for Children With Asthma , 2001, Pediatrics.

[46]  N Franklin Adkinson,et al.  Long-term effects of budesonide or nedocromil in children with asthma. , 2000, The New England journal of medicine.

[47]  R. Pauwels,et al.  Low-dose inhaled corticosteroids and the prevention of death from asthma. , 2000, The New England journal of medicine.

[48]  H. Anttila,et al.  Salmeterol/fluticasone propionate (50/100 μg) in combination in a Diskus™ inhaler (Seretide™) is effective and safe in children with asthma , 2000, Pediatric pulmonology.

[49]  F. Thien,et al.  An antiinflammatory effect of salmeterol, a long-acting beta(2) agonist, assessed in airway biopsies and bronchoalveolar lavage in asthma. , 1999, American journal of respiratory and critical care medicine.

[50]  J. Heyder,et al.  Glucocorticoids ablate IL-1β-induced β-adrenergic hyporesponsiveness in human airway smooth muscle cells. , 1999, American journal of physiology. Lung cellular and molecular physiology.

[51]  M. Demedts,et al.  SWITCH TO NON‐CFC INHALED CORTICOSTEROIDS: A COMPARATIVE EFFICACY STUDY OF HFA‐BDP AND CFC‐BDP METERED‐DOSE INHALERS , 1999, International journal of clinical practice.

[52]  M. W. Jensen,et al.  A dose-dependent effect of the novel inhaled corticosteroid ciclesonide on airway responsiveness to adenosine-5'-monophosphate in asthmatic patients. , 1999, American journal of respiratory and critical care medicine.

[53]  H. Bisgaard,et al.  The effect of inhaled fluticasone propionate in the treatment of young asthmatic children: a dose comparison study. , 1999, American journal of respiratory and critical care medicine.

[54]  B. Rowe,et al.  Inhaled budesonide in addition to oral corticosteroids to prevent asthma relapse following discharge from the emergency department: a randomized controlled trial. , 1999, JAMA.

[55]  S. Szefler,et al.  Dose-related efficacy of budesonide administered via a dry powder inhaler in the treatment of children with moderate to severe persistent asthma. , 1998, The Journal of pediatrics.

[56]  T L Petty,et al.  Budesonide delivered by Turbuhaler is effective in a dose-dependent fashion when used in the treatment of adult patients with chronic asthma. , 1998, The Journal of allergy and clinical immunology.

[57]  C. Rodrigo,et al.  Inhaled flunisolide for acute severe asthma. , 1998, American journal of respiratory and critical care medicine.

[58]  B. Lipworth,et al.  Adrenocortical activity with repeated twice daily dosing of fluticasone propionate and budesonide given via a large volume spacer to asthmatic school children. , 1997, Thorax.

[59]  Third Expert Panel on theDiagnosis,et al.  Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma , 1997 .

[60]  A. Woolcock,et al.  Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. , 1996, American journal of respiratory and critical care medicine.

[61]  H. Neijens,et al.  Effect of long-term treatment with inhaled corticosteroids and beta-agonists on the bronchial responsiveness in children with asthma. , 1987, The Journal of allergy and clinical immunology.

[62]  T. Seemungal,et al.  The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. , 2008, American journal of respiratory and critical care medicine.

[63]  T. Gulliver,et al.  Inhaled Corticosteroids in Children with Asthma , 2007, Paediatric drugs.

[64]  P. Dorinsky,et al.  The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. , 2006, Chest.

[65]  N. P. Adamsa,et al.  The dose – response characteristics of inhaled corticosteroids when used to treat asthma : An overview of Cochrane systematic reviews , 2006 .

[66]  P. Jones,et al.  Inhaled fluticasone at different doses for chronic asthma in adults and children. , 2005, The Cochrane database of systematic reviews.

[67]  A. Wanner,et al.  Nongenomic actions of glucocorticosteroids on the airway vasculature in asthma. , 2004, Proceedings of the American Thoracic Society.

[68]  J. Corren,et al.  Hydrofluoroalkane Formulations of Inhaled Corticosteroids for the Treatment of Asthma , 2004, Treatments in respiratory medicine.

[69]  S. Atiş,et al.  Adrenal suppression from high-dose inhaled fluticasone propionate in children with asthma , 2004 .

[70]  P. Barry,et al.  Comparison of the effectiveness of inhaler devices in asthma and chronic obstructive airways disease: a systematic review of the literature. , 2001, Health technology assessment.

[71]  Edersen,et al.  EFFECT OF LONG-TERM TREATMENT WITH INHALED BUDESONIDE ON ADULT HEIGHT IN CHILDREN WITH ASTHMA , 2000 .

[72]  Ennis,et al.  A Comparison of Inhaled Fluticasone and Oral Prednisone for Children with Severe Acute Asthma , 2000 .

[73]  P. Barnes,et al.  Glucocorticosteroids increase beta 2-adrenergic receptor transcription in human lung. , 1995, The American journal of physiology.